SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act 1934
Date of Report (Date of earliest event
reported):
(Exact name of registrant as specified in charter)
(State or other jurisdiction of incorporation)
|
|
| |
| (Commission File Number) | (IRS Employer Identification No.) |
|
|
| |
| (Address of principal executive offices) | (Zip Code) | |
| Registrant’s telephone number, including area code: |
+1 | |
|
N/A (Former name or former address, if changed since last report) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| N/A | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 9, 2024, the Shareholders of Nemaura Medical Inc. (the “Company”) approved by written consent to authorize amendments to the Articles of Incorporation of the Company (the “Articles”) to effect a reverse stock split of the common stock, par value $0.001 per share, of the Company (the “Common Stock”) ranging in ratio between 1-for-10 and 1-for-150, with one share of Common Stock being issued for a range of between each 10 and 150 shares of Common Stock issued and outstanding, with such final ratio to be determined by the Board following approval thereof by the shareholders of the Company, with any fractional shares of Common Stock resulting therefrom being rounded up to the nearest whole share of Common Stock (the “Reverse Split”), and to amend the Articles to effect the Reverse Split.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. |
Description | |
| 104 | Cover Page Interactive Data File - the cover page XBRL tags are embedded with the Inline XBRL document | |
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| NEMAURA MEDICAL INC. | ||
| Date: May 17, 2024 | By: | /s/ Dewan F.H. Chowdhury |
| Dewan F.H. Chowdhury Chief Executive Officer |
||
Cover |
May 09, 2024 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | May 09, 2024 |
| Entity File Number | 001-38355 |
| Entity Registrant Name | NEMAURA MEDICAL INC. |
| Entity Central Index Key | 0001602078 |
| Entity Tax Identification Number | 46-5027260 |
| Entity Incorporation, State or Country Code | NV |
| Entity Address, Address Line One | 57 West 57th Street |
| Entity Address, City or Town | Manhattan |
| Entity Address, State or Province | NY |
| Entity Address, Postal Zip Code | 10019 |
| City Area Code | (646) |
| Local Phone Number | 416-8000 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Entity Emerging Growth Company | false |